---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-074292"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2026-06-16T11:00:33+00:00"
generated_at: "2026-06-16T11:06:14.023648+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics prices $500M 0% convertible notes due 2031 to refinance 2026 notes

## Summary
- Priced $500M aggregate principal of 0% Convertible Senior Notes due 2031; initial purchasers have option for additional $50M.
- Conversion price set at $107.48 per share, a 40% premium over June 15 closing price of $76.77.
- Approximately $328.8M of net proceeds will be used to repurchase $222M of outstanding 1.5% convertible notes due 2026.
- Closing expected on June 18, 2026; notes are senior unsecured obligations and mature June 15, 2031.
- Remaining net proceeds will be used for general corporate purposes, including potential additional repurchases of 2026 notes.

## SEC filing metadata
- accession: 0001104659-26-074292
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2026-06-16T11:00:33+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000110465926074292/0001104659-26-074292-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000110465926074292/tm2618041d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-074292
- JSON: https://secwatch.observer/filing/0001104659-26-074292.json
- Plain text: https://secwatch.observer/filing/0001104659-26-074292.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.